The clinical efficacy of fluconazole in the treatment of vulvovaginal candidiasis
https://doi.org/10.21518/2079-701X-2016-2-60-63
Abstract
The article tells about the key problems of diagnosis and treatment of patients with vulvovaginal candidiasis (VVC). Candida albicans causes 75--80% of candidiasis cases. Clinical forms of VVC include: Candida-carrying, acute VVC, chronic (recurrent) vulvovaginal candidiasis (CRVVC). The main diagnostic approaches to the treatment and prevention of recurrence of the disease are described. The authors presented data on the efficacy of the antifungal medication Diflucan in the fight against VVC.
About the Authors
V. N. Serov
Scientific center for obstetrics, gynecology and perinatology named after acad. V.I. Kulakov
Russian Federation
Russian Federation
N. A. Buralkina
Scientific center for obstetrics, gynecology and perinatology named after acad. V.I. Kulakov
Russian Federation
Russian Federation
M. Y. Borisenko
Scientific center for obstetrics, gynecology and perinatology named after acad. V.I. Kulakov
Russian Federation
Russian Federation
F. Sh. Mamedova
Scientific center for obstetrics, gynecology and perinatology named after acad. V.I. Kulakov
Russian Federation
Russian Federation
References
1. Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Candida vaginitis: self- reported incidence and associated costs. Sex Transm Dis, 2000, 27: 230-235.
2. Ogouyemi-Hounto A, Adisso S, Djamal J, Sanni R, Amangbegnon R, Biokou-Bankole B, Kinde Gazard D,Massougbodji A. Place of vulvovaginal candidiasis in the lower genital tract infections and associated risk factors among women in Benin. J Mycol Med., 2014 Jun, 24(2): 100-5.
3. Uvarova EV. Vulvovaginal candidiasis in girls (guidelines for a practitioner). Antibiot Khimioter., 2007, 52(4-5): 49-55. [Article in Russian]
4. Hoffmann JN, You HM, Hedberg EC, Jordan JA, McClintock MK. Prevalence of bacterial vagi-nosis and Candida among postmenopausal women in the United States. J Gerontol B Psychol Sci SocSci., 2014, Nov, 69 Suppl 2: S205-14.
5. Hamad M, Kazandji N, Awadallah S, Allam H. Prevalence and epidemiological characteristics of vaginal candidiasis in the UAE. Mycoses., 2014 Mar, 57(3): 184-90.
6. Руководство по амбулаторно-поликлинической помощи в акушерстве и гинекологии под редакцией акад. В.И. Кулакова, проф. В.Н. Прилепской, В.Е. Радзинского. М.: «ГЭОТАР-Медиа», 2006. с. 1029.
7. Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin North Am., 2008, 22: 637-52.
8. Baykushev R, Ouzounova-Raykova V, Stoykova V, Mitov I. Reliable microbiological diagnosis of vulvovaginal candidiasis. Akush Ginekol (Sofiia), 2014, 53(4): 17-20.
9. Bassyouni RH, Wegdan AA, Abdelmoneim A, Said W, AboElnaga F. Phospholipase and Aspartyl Proteinase Activities of Candida Species Causing Vulvovaginal Candidiasis in Patients with Type 2 Diabetes Mellitus. J Microbiol Biotechnol., 2015, Oct 28, 25(10): 1734-41.
10. Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG, 2015, May, 122(6): 785-94.
11. Beigi RH, Meyn LA, Moore DM, Krohn MA, Hillier SL. Vaginal yeast colonization in non-pregnant women: a longitudinal study. Obstet Gynecol., 2004, 104: 926-30.
12. Gongalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol., 2015, Dec, 21: 1-23.
13. Aguin TJ, Sobel JD. Vulvovaginal candidiasis in pregnancy. Curr Infect Dis Rep., 2015 Jun, 17(6): 462.
14. Kimberly A. Workowski et al. Sexually Transmitted Diseases Treatment Guidelines. MMWR, 2010, 59(RR12): 1-110.
15. Sherrard J, Donders G, White D. European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge. International Journal of STD & AIDS, 2011, 22: 421-429.
16. Glockner A, Cornely OA. Candida glabrata-unique features and challenges in the clinical management of invasive infections. Mycoses., 2015, Aug, 58(8): 445-50.
17. Li H, Zhang C, Chen Z, Shi W, Sun S. A promising approach of overcoming the intrinsic resistance of Candida krusei to fluconazole (FLC) - combining tacrolimus with FLC. FEMS Yeast Res., 2014, Aug, 14(5): 808-11.
18. Fan S, Liu X, Wu C, Xu L, Li J. Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis. Mycopathologia, 2015, Feb, 179(1-2): 95-101.
19. White DJ, Habib AR, Vanthuyne A, Langford S, Symonds M. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm Infect., 2001 Jun, 77(3): 212-3.
20. Szweda P, Gucwa K, Romanowska E, Dzierzanowska-Fangrat K, Naumiuk L, Brillowska-Dabrowska A, Wojciechowska-Koszko I, Milewski S. Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland. J Med Microbiol., 2015. Jun, 64(6): 610-9.
21. Deorukhkar SC, Saini S. Echinocandin susceptibility profile of fluconazole resistant Candida species isolated from blood stream infections. Infect Disord Drug Targets, 2015, Dec 9.
22. Shekari Ebrahim Abad H, Zaini F, Kordbacheh P, Mahmoudi M, Safara M, Mortezaee V. In Vitro Activity of Caspofungin Against Fluconazole-Resistant Candida Species Isolated From Clinical Samples in Iran. Jundishapur J Microbiol., 2015, Jun 27, 8(6).
23. Guidelines for outpatient care in obstetrics and gynecology ed. by V.I. Kulakov, prof. V.N. Prilepskaya, V.E. Radzinsky "GEOTAR-Media", 2006. p. 1029.
Review
For citations:
Serov VN, Buralkina NA, Borisenko MY, Mamedova FS. The clinical efficacy of fluconazole in the treatment of vulvovaginal candidiasis. Meditsinskiy sovet = Medical Council. 2016;(2):60-63. (In Russ.) https://doi.org/10.21518/2079-701X-2016-2-60-63
Views:
869
Email this article 